| PUBLIC-AND-PRIVATE-HOSPITALS-IN-SINGAPORE |
PUBLIC-AND-PRIVATE-HOSPITALS-IN-SINGAPORE |
90%
|
We are dependent on our major customers which primarily consist of public and private hospitals in Singapore. |
| PTE-LTD |
PTE-LTD |
85%
|
Pte. Ltd., through which we gain access to Aiodine’s proprietary iodine-based technology, intellectual property, and technical expertise for the worldwide commercialization of iodine-based wound care… |
| SNNUF |
Smith & Nephew plc |
72%
|
Reciprocal relationship from SNNUF graph: Reciprocal relationship from CUPR graph: , our maggot-based chronic wound care products are subsidized under the MediSave Scheme and classified as one of the… |
| SNNUF |
Smith & Nephew plc |
72%
|
, our maggot-based chronic wound care products are subsidized under the MediSave Scheme and classified as one of the approved inpatient day surgery treatment options. Under the MediSave payment schem… |
| AIODINE-LABORATORY-PTE-LTD |
AIODINE-LABORATORY-PTE-LTD |
62%
|
actual sales of our future products that we did not anticipate prior to commercialization, which may require us to adjust our sales and marketing strategy, recruit additional personnel, or incur unfo… |
| AIODINE-PTE-LTD |
AIODINE-PTE-LTD |
62%
|
actual sales of our future products that we did not anticipate prior to commercialization, which may require us to adjust our sales and marketing strategy, recruit additional personnel, or incur unfo… |
| ENGINEERING-LIMITED |
ENGINEERING-LIMITED |
62%
|
iotech and Engineering Limited, or Advanced Biotech Primary objective We granted Advanced Biotech a sole and exclusive, non-transferable, non-sub-licensable, non-assignable, license to develop, marke… |
| IMARC-GROUP |
IMARC-GROUP |
62%
|
imated at USD 1.04 billion in 2026, and is expected to reach USD 1.39 billion by 2031, growing at a CAGR of 6.02% from 2026 to 2031. Mainland China is getting more requests for wound care management … |
| NAME-BACKGROUND-OWNERSHIP-CUPRINA-HOLDINGS |
NAME-BACKGROUND-OWNERSHIP-CUPRINA-HOLDINGS |
62%
|
rate Law”. 27 If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business… |
| SHANGHAI-ZHANGJIANG-YIDIANTONG-TECHNOLOGY-CO-LTD |
SHANGHAI-ZHANGJIANG-YIDIANTONG-TECHNOLOGY-CO-LTD |
62%
|
iotech and Engineering Limited, or Advanced Biotech Primary objective We granted Advanced Biotech a sole and exclusive, non-transferable, non-sub-licensable, non-assignable, license to develop, marke… |
| WHATSAPP-GROUP |
WHATSAPP-GROUP |
62%
|
rate Law”. 27 If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business… |
| ZHEJIANG-HELIANG-TECHNOLOGY-CO-LTD |
ZHEJIANG-HELIANG-TECHNOLOGY-CO-LTD |
62%
|
ense Agreement in August 2025, the material terms of which are set out below: Parties i. Cuprina Pte. Ltd. ii. Zhejiang Heliang Technology Co., Ltd. Primary objectives Exclusive licensing and commerc… |
